Objective
To validate CT-based longitudinal markers of the progression of
Alzheimer's disease (AD).
Materials and Methods
We retrospectively studied 33 AD patients and 39 non-demented
patients with other neurological illnesses (Non-AD) having 4–12 CT
exams of the head, over 3.9 ± 1.7 years. At each time point we
applied an automatic software to measure whole brain, CSF, and intracranial
space (ICS) volumes. Longitudinal measures were then related to disease
status and time since first scan using hierarchical models.
Results
Absolute brain volume loss accelerated for non-AD patients by 0.86
ml/yr2 (95%C.I. 0.64 to 1.08 ml/yr2) and
1.5× faster, i.e. 1.32 ml/yr2 (95%C.I. 1.09 to
1.56 ml/yr2) for AD patients (p= 0.006). In terms of
brain volume normalized to ICS, the acceleration in atrophy rate for non-AD
patients was 0.0578%/yr2 (95%C.I.
0.0389%/yr2 to 0.0767%/yr2) again,
1.5× faster, i.e. 0.0919%/yr2 (95% C.I.
0.0716%/yr2 to 0.1122%/yr2) for AD
patients (p= 0.017). This translates to an increase in atrophy rate
from 0.5% to 1.4% in AD versus to 1.1% in non-AD
group after 10 years.
Conclusion
Brain volumetry on CT reliably detected accelerated volume loss in AD
and significantly lower acceleration factor in age-matched non-AD patients,
leading to the possibility of its use to monitor the progression of
cognitive decline and dementia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.